Solventum to Acquire Acera Surgical for Up to $850 Million

Reuters11-20

<a href="https://laohu8.com/S/SOLV">Solventum</a> to Acquire Acera Surgical for Up to $850 Million

Solventum is set to acquire Acera Surgical, a privately held bioscience company specializing in fully engineered materials for regenerative wound care, for $725 million in cash and up to $125 million in additional contingent payments based on certain future milestones. The deal will expand Solventum's MedSurg portfolio into the synthetic tissue matrices technology space, targeting the fast-growing $900 million U.S. market segment within acute care. Acera is projected to generate approximately $90 million in sales in 2025. The transaction is expected to close in the first half of 2026, with Solventum using cash on hand for the purchase. The acquisition is anticipated to be slightly dilutive to adjusted earnings per share in 2026, becoming accretive in 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Solventum Corporation published the original content used to generate this news brief via PR Newswire (Ref. ID: CG29583) on November 20, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2584326137?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-20 22:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2584326137","market":"nz","top_or_hot":-1,"title":"Solventum to Acquire Acera Surgical for Up to $850 Million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/SOLV\">Solventum</a> to Acquire Acera Surgical for Up to $850 Million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Solventum is set to acquire Acera Surgical, a privately held bioscience company specializing in fully engineered materials for regenerative wound care, for $725 million in cash and up to $125 million in additional contingent payments based on certain future milestones. The deal will expand Solventum's MedSurg portfolio into the synthetic tissue matrices technology space, targeting the fast-growing $900 million U.S. market segment within acute care. Acera is projected to generate approximately $90 million in sales in 2025. The transaction is expected to close in the first half of 2026, with Solventum using cash on hand for the purchase. The acquisition is anticipated to be slightly dilutive to adjusted earnings per share in 2026, becoming accretive in 2027.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Solventum Corporation published the original content used to generate this news brief via PR Newswire (Ref. ID: CG29583) on November 20, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Solventum to Acquire Acera Surgical for Up to $850 Million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSolventum to Acquire Acera Surgical for Up to $850 Million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-20 22:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/SOLV\">Solventum</a> to Acquire Acera Surgical for Up to $850 Million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Solventum is set to acquire Acera Surgical, a privately held bioscience company specializing in fully engineered materials for regenerative wound care, for $725 million in cash and up to $125 million in additional contingent payments based on certain future milestones. The deal will expand Solventum's MedSurg portfolio into the synthetic tissue matrices technology space, targeting the fast-growing $900 million U.S. market segment within acute care. Acera is projected to generate approximately $90 million in sales in 2025. The transaction is expected to close in the first half of 2026, with Solventum using cash on hand for the purchase. The acquisition is anticipated to be slightly dilutive to adjusted earnings per share in 2026, becoming accretive in 2027.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Solventum Corporation published the original content used to generate this news brief via PR Newswire (Ref. ID: CG29583) on November 20, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SOLV","symbol_name":"Solventum","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251120:nNDL35Wpzh:1","article_id":"2584326137","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2584326137","pubTimestamp":1763647252,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Solventum is set to acquire Acera Surgical, a privately held bioscience company specializing in fully engineered materials for regenerative wound care, for $725 million in cash and up to $125 million in additional contingent payments based on certain future milestones. The deal will expand Solventum's MedSurg portfolio into the synthetic tissue matrices technology space, targeting the fast-growing $900 million U.S. market segment within acute care. Acera is projected to generate approximately $90 million in sales in 2025. The transaction is expected to close in the first half of 2026, with Solventum using cash on hand for the purchase. The acquisition is anticipated to be slightly dilutive to adjusted earnings per share in 2026, becoming accretive in 2027.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SOLV":"Solventum","BK4198":"医疗保健用品"},"translate_title":"Solventum将以高达8.5亿美元收购Acera Surgical","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SOLV":0.9},"content_text":"Solventum to Acquire Acera Surgical for Up to $850 Million\n    \n\n        Solventum is set to acquire Acera Surgical, a privately held bioscience company specializing in fully engineered materials for regenerative wound care, for $725 million in cash and up to $125 million in additional contingent payments based on certain future milestones. The deal will expand Solventum's MedSurg portfolio into the synthetic tissue matrices technology space, targeting the fast-growing $900 million U.S. market segment within acute care. Acera is projected to generate approximately $90 million in sales in 2025. The transaction is expected to close in the first half of 2026, with Solventum using cash on hand for the purchase. The acquisition is anticipated to be slightly dilutive to adjusted earnings per share in 2026, becoming accretive in 2027.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Solventum Corporation published the original content used to generate this news brief via PR Newswire (Ref. ID: CG29583) on November 20, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2584326137","isCrawlerRequest":true}